Introduction
IgA nephropathy is one of the most common forms of primary glomerular disease worldwide. It primarily affects the kidneys’ filtering units (glomeruli) and can lead to blood in urine, protein leakage, and progressive kidney dysfunction over time. Although some individuals experience a mild course, others may gradually develop chronic kidney disease if not properly monitored and managed.
This condition is sometimes referred to as Berger’s disease, named after the French physician who first described it. Despite being recognized for decades, IgA nephropathy remains a complex disorder involving immune system dysfunction, genetic predisposition, and environmental triggers.
This article provides a comprehensive overview of IgA nephropathy, including its pathophysiology, clinical features, diagnostic approach, treatment strategies, dietary considerations, and long-term outlook.
What is IgA?
Immunoglobulin A (IgA) is a type of antibody produced by the immune system. It plays a critical role in defending mucosal surfaces such as the respiratory tract, gastrointestinal tract, and genitourinary system. IgA helps neutralize pathogens before they invade deeper tissues.
There are two main forms of IgA:
- Serum IgA (circulating in the blood)
- Secretory IgA (present in saliva, tears, and mucosal secretions)
In IgA nephropathy, the immune system produces an abnormal form of IgA. These abnormal IgA molecules accumulate in the glomeruli, triggering inflammation and progressive kidney damage.
Epidemiology
IgA nephropathy is more common in:
- Young adults (second and third decades of life)
- Males (slightly more than females)
- Certain geographic regions such as East Asia and parts of Europe
It can occur in children and older adults as well, though presentation and progression may vary.
Pathophysiology
The development of IgA nephropathy involves multiple steps:
1. Production of Abnormal IgA
The body produces IgA with abnormal glycosylation (defective sugar molecules attached to the antibody). These abnormal IgA molecules are recognized as foreign by the immune system.
2. Formation of Immune Complexes
The immune system produces antibodies against the abnormal IgA. This leads to the formation of immune complexes in the bloodstream.
3. Deposition in the Glomeruli
These immune complexes deposit in the mesangium (a structural area within the glomerulus). This triggers local inflammation.
4. Inflammatory Cascade
Inflammation causes:
- Mesangial cell proliferation
- Release of cytokines
- Damage to the filtration barrier
Over time, repeated injury may lead to:
- Glomerulosclerosis (scarring)
- Tubulointerstitial fibrosis
- Progressive decline in kidney function
Risk Factors
Several factors may increase the risk of developing IgA nephropathy:
- Genetic predisposition
- Family history of kidney disease
- Recurrent respiratory or gastrointestinal infections
- Liver diseases
- Autoimmune disorders
Certain genetic markers are associated with increased susceptibility, suggesting a hereditary component.
Clinical Features
The presentation of IgA nephropathy varies widely.
1. Hematuria
The most common symptom is blood in urine. It may be:
- Microscopic (detected only on lab testing)
- Gross (visible reddish or cola-colored urine)
Gross hematuria often occurs after upper respiratory infections.
2. Proteinuria
Protein leakage into urine may range from mild to nephrotic levels.
3. Hypertension
Elevated blood pressure is common in progressive cases.
4. Edema
Swelling of legs or face may occur if significant protein loss develops.
5. Asymptomatic Detection
Some individuals are diagnosed incidentally during routine urine examination.
Diagnostic Criteria
1. Urine Examination
- Presence of red blood cells
- Dysmorphic RBCs
- Proteinuria
2. Blood Tests
- Serum creatinine
- Estimated glomerular filtration rate (eGFR)
- Serum IgA levels (may be elevated but not diagnostic)
3. Kidney Biopsy (Gold Standard)
Definitive diagnosis requires kidney biopsy. Immunofluorescence microscopy shows dominant IgA deposition in the mesangium.
Histological grading systems help predict disease progression based on:
- Mesangial hypercellularity
- Endocapillary proliferation
- Segmental sclerosis
- Tubular atrophy
- Interstitial fibrosis
Differential Diagnosis
Conditions that may resemble IgA nephropathy include:
- Post-infectious glomerulonephritis
- Lupus nephritis
- Alport syndrome
- Henoch–Schönlein purpura (IgA vasculitis)
Proper evaluation is necessary to distinguish between these conditions.
Treatment and Management
Management depends on severity, degree of proteinuria, and kidney function.
1. Supportive Therapy
This is the foundation of treatment.
Blood Pressure Control
ACE inhibitors or ARBs are preferred because they:
- Reduce proteinuria
- Protect kidney function
- Lower blood pressure
Target blood pressure is generally below 130/80 mmHg.
Proteinuria Reduction
Controlling protein loss is critical for slowing progression.
2. Immunosuppressive Therapy
In selected patients with persistent proteinuria despite optimal supportive care:
- Corticosteroids may be considered
- Other immunosuppressive agents may be used in high-risk cases
Treatment decisions must balance potential benefits with side effects.
3. Emerging Therapies
Newer therapies aim to:
- Reduce abnormal IgA production
- Modulate immune response
- Target complement activation
Research continues to improve outcomes and minimize treatment toxicity.
Role of Diet in IgA Nephropathy
Diet plays an important supportive role.
1. Sodium Restriction
Limiting salt intake helps control blood pressure and reduce fluid retention.
2. Protein Intake
Moderate protein intake may help reduce kidney workload. Excessive protein should be avoided.
3. Potassium and Phosphorus
In advanced kidney disease, monitoring potassium and phosphorus becomes important.
4. Healthy Eating Pattern
- Fresh fruits and vegetables
- Whole grains
- Limited processed foods
- Adequate hydration
Dietary modifications should be individualized based on kidney function and laboratory values.
Complications
If left uncontrolled, IgA nephropathy can lead to:
- Chronic kidney disease
- Nephrotic syndrome
- Hypertension
- End-stage kidney disease
- Cardiovascular complications
Approximately 20–40% of patients may progress to advanced kidney disease over 20 years.
Prognosis
The course of IgA nephropathy is variable.
Favorable Prognostic Factors:
- Minimal proteinuria
- Normal blood pressure
- Stable kidney function
Poor Prognostic Factors:
- Persistent high proteinuria
- Hypertension
- Reduced eGFR at diagnosis
- Severe biopsy findings
Early detection and consistent follow-up significantly improve long-term outcomes.
Monitoring and Follow-Up
Regular follow-up includes:
- Blood pressure monitoring
- Urine protein estimation
- Serum creatinine and eGFR
- Periodic clinical evaluation
Monitoring helps detect progression early and adjust treatment accordingly.
Prevention Strategies
While primary prevention is not well established, progression can be slowed by:
- Strict blood pressure control
- Avoiding unnecessary painkillers (NSAIDs)
- Maintaining healthy body weight
- Managing infections promptly
- Adhering to prescribed medications
Psychological Impact
Chronic kidney conditions can cause emotional stress. Patients may experience anxiety about long-term kidney health. Counseling and support groups may help improve coping and adherence to therapy.
Research and Future Directions
Current research focuses on:
- Understanding genetic susceptibility
- Identifying biomarkers for early detection
- Developing targeted immunotherapy
- Exploring complement pathway inhibitors
Advancements in molecular medicine are likely to reshape management strategies in the coming years.
Conclusion
IgA nephropathy is a common but complex kidney disorder involving immune-mediated damage to the glomeruli. Its presentation ranges from mild hematuria to progressive kidney failure. Early diagnosis, careful monitoring, optimal blood pressure control, and appropriate therapeutic interventions can significantly slow disease progression.
Individualized care, lifestyle modifications, and ongoing research offer hope for improved long-term outcomes. With proper management, many patients maintain stable kidney function for years.
Frequently Asked Questions (FAQs)
Is IgA nephropathy hereditary?
It can run in families, suggesting a genetic component, but not all cases are inherited.
Can IgA nephropathy be cured?
Currently, there is no complete cure, but progression can be slowed significantly with proper management.
Why does blood in urine occur after infections?
Respiratory infections stimulate IgA production, increasing immune complex formation and kidney inflammation.
Does everyone with IgA nephropathy develop kidney failure?
No. Many individuals maintain stable kidney function for decades.
Is kidney biopsy always necessary?
Yes, a biopsy is required for definitive diagnosis.
Can diet alone treat IgA nephropathy?
Diet supports management but cannot replace medical therapy.
Are steroids safe in IgA nephropathy?
They may be beneficial in selected cases but must be used carefully due to side effects.
How often should monitoring be done?
Frequency depends on severity, but typically every 3–6 months in stable patients.
Can pregnancy affect IgA nephropathy?
Women with stable kidney function often have good outcomes, but high-risk cases need close supervision.
What lifestyle changes are important?
Controlling blood pressure, reducing salt intake, maintaining healthy weight, and avoiding nephrotoxic drugs are crucial.